JPM 2024 Roundup: Abbott And Medtronic Push Diabetes Tech, Edwards Updates Tricuspid Progress, Shockwave Bets On R&D

Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.

J.P. Morgan 2024
• Source: Shutterstock

Abbott expects sales of its successful FreeStyle Libre line of continuous glucose monitoring (GCM) systems to be worth $10bn in revenue annually by 2028.

The company expects Libre sales to reach nearly $5bn this year. (Also see "Dexcom Tries To Close Gap On...

More from Strategy

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.  

MI-Business (Free-2): Prison Is the First Mental Health Visit for Many in Spain

 
• By 

Spain has one of the highest incarceration rates in Europe, with 160 individuals imprisoned per 100,000 residents. In 2020, 43,494 people were incarcerated in facilities not managed by regional health authorities — essentially all regions except Catalonia, the Basque Country, and Navarra.

News We’re Watching: Neuralink’s Blindsight Gets FDA Breakthrough Device Tag; FDA Pump Recalls, Guidances; Discure, DeepLook Bolster Coffers

This week, Neuralink announced it received US FDA breakthrough device designation for a device to restore sight; medtechs Discure and DeepLook secured new funding; FDA pump recalls from B. Braun Medical and Fresenius Kabi; Axonics prevails in patent infringement lawsuit with Medtronic; Merit Medical buys Cook Medical for $210m.

FDA Releases Six More De Novo Summaries

 
• By 

The US FDA released six more device classifications in early September, including products from Edwards, Interscope, and Baxter Healthcare.

More from Business

test carousel-Medtech

 
• By 

test carousel-Medtech

test carousel

 
• By 

test carousel-HBW

News We’re Watching: New FDA Approvals For Breast Implant, Colon Cancer Test, Imaging Agent; TAP Expansion, AI Standards

This week, Establishment Labs Holdings announced the FDA gave it premarket approval for Motiva breast implant, Cologuard lands FDA approval for Cologuard Plus and GE HealthCare gets FDA nod for a new imaging agent. The FDA announces another expansion for TAP into ophthalmology and radiology. The AAMI and CTA will join forces to develop standards for AI and ML-enabled health care products.